Enclomiphene Treatment in Hypogonadal Men

Introduction to Enclomiphene and IGF-1

IGF-1 plays a crucial role in cardiac function, regulating physiological cardiac hypertrophy, and has stimulatory effects on myocardial contractility through calcium handling, as stated by the American Heart Association and the American College of Cardiology 1
Reduced IGF-1 levels may impact cardiac function, potentially reducing thermodynamic efficiency of the contractile apparatus, highlighting the importance of monitoring IGF-1 levels in clinical practice 1

A complete pituitary hormone assessment, including IGF-1 levels, is recommended before initiating enclomiphene treatment, as suggested by the Endocrine Society and the American Association of Clinical Endocrinologists 2
Regular IGF-1 measurements during enclomiphene treatment are necessary to monitor for potential adverse effects on cardiovascular health and bone density, according to the American Association of Clinical Endocrinologists 2

The American College of Cardiology recommends considering lower doses of enclomiphene (6.25mg) if IGF-1 reduction is concerning, to minimize potential adverse effects on cardiovascular health 1
Comprehensive pituitary function testing is recommended before initiating enclomiphene, and regular follow-up imaging if structural pituitary abnormality is identified, as stated by the Neurosurgery society and the Endocrine Society 2, 3

Neglecting to monitor IGF-1 levels during enclomiphene treatment may miss clinically significant reductions, which can impact cardiac function and bone mineral density, according to the American Heart Association and the Endocrine Society 1, 4
Focusing only on testosterone levels may mask the negative impact on the GH/IGF-1 axis, highlighting the importance of monitoring both parameters, as suggested by the Endocrine Society 2
IGF-1 has various physiological roles, including promoting glucose uptake, influencing insulin sensitivity, regulating bone formation, and promoting protein synthesis and muscle growth, as noted by the British Journal of Sports Medicine and other guideline societies 5, 4

Management of low IGF-1 levels should target the underlying cause, including nutritional interventions and hormone replacement therapy, as recommended by various clinical guidelines 4
The following conditions and their management are recommended:

Condition	Management
Malnutrition or low energy availability	Increase caloric intake, target energy availability ≥45 kcal/kg of fat-free mass [4]
Hypothyroidism	Initiate thyroid hormone replacement [6]
Pituitary adenoma or other structural abnormality	Refer to neurosurgery for evaluation, consider medical therapy based on adenoma type [3]
GH deficiency	Consider GH replacement therapy based on clinical presentation and severity of deficiency [7, 3]

Verifying low IGF-1 using age-specific and sex-specific reference ranges, and assessing nutritional status and energy availability is recommended by the British Journal of Sports Medicine 4
Checking thyroid function (TSH, free T4) to rule out non-GH deficiency causes is suggested by the Hypertension journal 6
Evaluating for GH deficiency using GH stimulation testing and pituitary MRI to evaluate for structural abnormalities is recommended by the Nature Reviews Endocrinology journal 3

Regular IGF-1 measurements are recommended to assess treatment efficacy, and bone density assessment is recommended due to increased osteoporosis risk, as recommended by the British Journal of Sports Medicine and the Endocrine Society 4, 3
Regular follow-up imaging is necessary if structural pituitary abnormality is identified, as recommended by the Endocrine Society and the American College of Radiology 7, 3
Monitoring for development of other pituitary hormone deficiencies is suggested by the Nature Reviews Endocrinology journal 3
Multidisciplinary discussion for management decisions is recommended for non-functioning adenomas, as stated by the American Association of Neurological Surgeons 7